Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Hand-out
Press Releases
Ascletis Pharma Inc.  
November 12, 2024

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

-Phase III trial enrolled a total of 480 patients with moderate to severe acne

avatar profile Olean Times Herald

Olean Times Herald


Local & Social